Cargando…
Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716427/ https://www.ncbi.nlm.nih.gov/pubmed/31507425 http://dx.doi.org/10.3389/fphar.2019.00938 |
_version_ | 1783447373943406592 |
---|---|
author | Teopompi, Elisabetta Risé, Patrizia Pisi, Roberta Buccellati, Carola Aiello, Marina Pisi, Giovanna Tripodi, Candida Fainardi, Valentina Clini, Enrico Chetta, Alfredo Rovati, G. Enrico Sala, Angelo |
author_facet | Teopompi, Elisabetta Risé, Patrizia Pisi, Roberta Buccellati, Carola Aiello, Marina Pisi, Giovanna Tripodi, Candida Fainardi, Valentina Clini, Enrico Chetta, Alfredo Rovati, G. Enrico Sala, Angelo |
author_sort | Teopompi, Elisabetta |
collection | PubMed |
description | Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic acid (DHA), the precursor of specialized pro-resolving mediators. We hypothesized that DHA supplementation could restore the production of DHA-derived products and possibly contribute to a better control of the chronic pulmonary inflammation observed in CF subjects. Sputum samples from 15 CF and 10 chronic obstructive pulmonary disease (COPD) subjects were collected and analyzed by LC/MS/MS, and blood fatty acid were profiled by gas chromatography upon lipid extraction and transmethylation. Interestingly, CF subjects showed increased concentrations of leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and 15-hydroxyeicosatetraenoic acid (15-HETE), when compared with COPD patients, whereas the concentrations of DHA metabolites did not differ between the two groups. After DHA supplementation, not only DHA/arachidonic acid (AA) ratio and highly unsaturated fatty acid index were significantly increased in the subjects completing the study (p < 0.05) but also a reduction in LTB(4) and 15-HETE was observed, together with a tendency for a decrease in PGE(2,) and an increase in 17-hydroxy-docosahexaenoic acid (17OH-DHA) levels. At the end of the washout period, LTB(4), PGE(2), 15-HETE, and 17OH-DHA showed a trend to return to baseline values. In addition, 15-HETE/17OH-DHA ratio in the same sample significantly decreased after DHA supplementation (p < 0.01) when compared with baseline. In conclusion, our results show here that in CF patients, an impairment in fatty acid metabolism, characterized by increased AA-derived metabolites and decreased DHA-derived metabolites, could be partially corrected by DHA supplementation. |
format | Online Article Text |
id | pubmed-6716427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67164272019-09-10 Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation Teopompi, Elisabetta Risé, Patrizia Pisi, Roberta Buccellati, Carola Aiello, Marina Pisi, Giovanna Tripodi, Candida Fainardi, Valentina Clini, Enrico Chetta, Alfredo Rovati, G. Enrico Sala, Angelo Front Pharmacol Pharmacology Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic acid (DHA), the precursor of specialized pro-resolving mediators. We hypothesized that DHA supplementation could restore the production of DHA-derived products and possibly contribute to a better control of the chronic pulmonary inflammation observed in CF subjects. Sputum samples from 15 CF and 10 chronic obstructive pulmonary disease (COPD) subjects were collected and analyzed by LC/MS/MS, and blood fatty acid were profiled by gas chromatography upon lipid extraction and transmethylation. Interestingly, CF subjects showed increased concentrations of leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and 15-hydroxyeicosatetraenoic acid (15-HETE), when compared with COPD patients, whereas the concentrations of DHA metabolites did not differ between the two groups. After DHA supplementation, not only DHA/arachidonic acid (AA) ratio and highly unsaturated fatty acid index were significantly increased in the subjects completing the study (p < 0.05) but also a reduction in LTB(4) and 15-HETE was observed, together with a tendency for a decrease in PGE(2,) and an increase in 17-hydroxy-docosahexaenoic acid (17OH-DHA) levels. At the end of the washout period, LTB(4), PGE(2), 15-HETE, and 17OH-DHA showed a trend to return to baseline values. In addition, 15-HETE/17OH-DHA ratio in the same sample significantly decreased after DHA supplementation (p < 0.01) when compared with baseline. In conclusion, our results show here that in CF patients, an impairment in fatty acid metabolism, characterized by increased AA-derived metabolites and decreased DHA-derived metabolites, could be partially corrected by DHA supplementation. Frontiers Media S.A. 2019-08-23 /pmc/articles/PMC6716427/ /pubmed/31507425 http://dx.doi.org/10.3389/fphar.2019.00938 Text en Copyright © 2019 Teopompi, Risé, Pisi, Buccellati, Aiello, Pisi, Tripodi, Fainardi, Clini, Chetta, Rovati and Sala http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Teopompi, Elisabetta Risé, Patrizia Pisi, Roberta Buccellati, Carola Aiello, Marina Pisi, Giovanna Tripodi, Candida Fainardi, Valentina Clini, Enrico Chetta, Alfredo Rovati, G. Enrico Sala, Angelo Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title | Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title_full | Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title_fullStr | Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title_full_unstemmed | Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title_short | Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation |
title_sort | arachidonic acid and docosahexaenoic acid metabolites in the airways of adults with cystic fibrosis: effect of docosahexaenoic acid supplementation |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716427/ https://www.ncbi.nlm.nih.gov/pubmed/31507425 http://dx.doi.org/10.3389/fphar.2019.00938 |
work_keys_str_mv | AT teopompielisabetta arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT risepatrizia arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT pisiroberta arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT buccellaticarola arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT aiellomarina arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT pisigiovanna arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT tripodicandida arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT fainardivalentina arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT clinienrico arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT chettaalfredo arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT rovatigenrico arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation AT salaangelo arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation |